Sign in to view content

Avacincaptad Pegol, A Novel C5 Inhibitor, and GATHER1 Study: Results From a Post-Hoc Analysis of Nascent Geographic Atrophy

Peter K. Kaiser, MD FASRS

Video
Published 2021

Related

Machine Learning Enabled Outer Retinal OCT Biomarker Extraction for Identification of High-Risk AMD Eyes for Subfoveal Geographic Atrophy Progression
Kubra Sarici, MD
Annual Meeting Talks
2021
Avacincaptad Pegol, A Novel C5 Inhibitor, Reached Statistical Significance in a Pivotal Clinical Trial for Geographic Atrophy Secondary to Dry AMD
Baruch D. Kuppermann, MD, PhD
Annual Meeting Talks
2020
Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial
Jason Hsu, MD
Annual Meeting Talks
2021

Category: AMD - Non-neovascular

See more